Endothelial-Cell Response
In cultured vascular endothelial cells, Vesugen was associated with changes in Ki-67, a marker of cell proliferation. This is a cellular finding, not proof of improved circulation. Endothelial study.
Back to Peptide Library
Vascular Bioregulator
Vesugen
KED Tripeptide • Endothelial Signaling • Vascular-Aging Research
Vesugen is the Lys-Glu-Asp (KED) tripeptide studied in endothelial, vascular smooth-muscle, and aging-related cell models. Its research signal has not established a treatment for circulation problems or an effective human injectable protocol.
At a glance
Vesugen Quick Reference
- Community research dose
- Members onlySign in to view dosing details.
- Reported route
- SubQ injectionCommunity convention, not an approved route
- Cycle
- Members onlySign in to view dosing details.
- Research focus
- Endothelial and vascular signalingCell studies; clinical benefit unproven
Overview
What Is Vesugen?
Vesugen is a synthetic three-amino-acid peptide made of lysine, glutamic acid, and aspartic acid (KED). It comes from the short-peptide bioregulator research tradition and is investigated primarily for vascular-cell signaling.
Published experiments have examined KED in cultured endothelial and smooth-muscle cells, gene-expression models, and aging-related vascular systems. These findings do not prove that injectable Vesugen improves circulation, prevents vascular disease, or changes cardiovascular outcomes in people.
Related bioregulator guides include Cardiogen and Prostamax.
Mechanism
Vesugen Mechanism of Action
Gene-Regulation Hypothesis
Molecular-docking work suggests KED may interact with a promoter region of the MKI67 gene. Docking proposes a mechanism; it does not establish the same interaction or clinical benefit in people. Docking and cell study.
Vascular-Cell Models
Other preclinical reports examine endothelial and smooth-muscle responses to KED. The evidence is concentrated in related research groups and needs independent replication.
Vascular-Aging Hypothesis
These signals motivate research into aging blood vessels, but do not establish treatment of atherosclerosis, hypertension, venous disease, or clotting disorders.
Research findings
Vesugen Benefits
Vesugen findings are mainly cellular and preclinical. Potential vascular effects are research hypotheses, not established medical benefits.
Current evidence level: laboratory and preclinical
Endothelial Signaling
Cell studies have measured proliferation markers in vessel-lining cells after KED exposure.
Vascular-Cell Research
Preclinical work explores endothelial and smooth-muscle responses; improved human vascular function has not been demonstrated.
Gene-Regulation Models
Docking and expression studies suggest a possible sequence-specific effect on cell-activity pathways.
Vascular-Aging Interest
Aging-related endothelial change is the central research context, not a validated anti-aging outcome.
Protocol planning
Vesugen Dosing Protocol
Members Access Only
Sign in or create a free account to view this content.
Preparation
Vesugen Reconstitution
Reconstitution Example
20mg vial + 3mL bacteriostatic water
Result6.67mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
2
Add diluent slowly
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
3
Dissolve gently
Swirl or roll the vial until the contents dissolve; do not shake.
4
Storage
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
Vesugen Community Experience
Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.
Positive Reports
- Circulation perception. Some users report warmer extremities, less leg heaviness, or steadier exercise tolerance.
- Venous comfort. Individual accounts describe less swelling or discomfort, without controlled confirmation.
- Short-cycle use. Satisfied users often report repeat courses rather than continuous use.
Negative & Mixed Reports
- Little noticeable effect. Some users report no clear change during a short cycle.
- Attribution is difficult. Dramatic circulation reports may involve other interventions or oral products.
- Occasional discomfort. Headache, flushing, dizziness, or injection-site irritation appear in some reports.
Stacking & synergy
Vesugen Stacking & Synergy
No controlled trials validate Vesugen combinations. These are community-discussed pairings, and any reported effect is difficult to attribute when compounds are started together.
Vesugen + GHK-Cu
A tissue-remodeling pairing: GHK-Cu has broader wound and extracellular-matrix research, while Vesugen has a vascular-cell focus. The combination is untested.
Vesugen + Pinealon
A community vascular-and-neural bioregulator pairing. No controlled evidence establishes improved cognition or circulation from combining them.
Vesugen + Epitalon
A healthy-aging pairing spanning vascular and circadian concepts, with no validated synergy and substantial attribution limits.
Safety notes
Vesugen Side Effects & Safety
Compound-specific human safety data are sparse. Cardiovascular symptoms should not be dismissed as an expected response to an experimental peptide.
Long-term injectable safety and interactions with cardiovascular medications have not been characterized.
Community Reports
- Many reports describe no obvious acute effect.
- Headache, flushing, dizziness, and injection-site irritation are occasionally reported.
- Reports are not sufficient to quantify adverse-event rates.
Unknowns
- No modern long-term injectable safety program is available.
- Formal cardiovascular interaction studies have not been conducted.
- Effects in people with vascular or clotting disorders remain unknown.
Vesugen Precautions
Avoid or Discuss With a Clinician If
- Pregnant or breastfeeding; safety data are unavailable.
- Known hypersensitivity to Vesugen or its components.
- Cardiovascular disease, uncontrolled blood pressure, clotting disorders, or unexplained vascular symptoms.
Use caution with
- Anticoagulants, antiplatelet drugs, antihypertensives, or vasodilators.
- Stimulants or other compounds that complicate cardiovascular monitoring.
Regulatory status: Vesugen is not FDA approved, and no established therapeutic dose or approved injectable use exists.
Final verdict
Peptide Protocols Verdict on Vesugen
Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion
Vesugen is one of the less-hyped bioregulators we find worth watching. Community feedback on circulation, recovery, and exercise tolerance is interesting, but these accounts are subjective and often involve other interventions.
We have looked at it as a short-cycle vascular bioregulator, sometimes alongside Pinealon. That pairing makes conceptual sense to us, though no combination data show it works better.
The endothelial-cell research gives Vesugen a coherent rationale. We would still want controlled human outcomes and proper cardiovascular safety data before treating it as more than an experimental option.